215 related articles for article (PubMed ID: 35255745)
1. L-Acetylcarnitine causes analgesia in mice modeling Fabry disease by up-regulating type-2 metabotropic glutamate receptors.
Formaggio F; Rimondini R; Delprete C; Scalia L; Merlo Pich E; Liguori R; Nicoletti F; Caprini M
Mol Pain; 2022; 18():17448069221087033. PubMed ID: 35255745
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.
Lakomá J; Rimondini R; Ferrer Montiel A; Donadio V; Liguori R; Caprini M
Mol Pain; 2016; 12():. PubMed ID: 27531673
[TBL] [Abstract][Full Text] [Related]
3. Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice.
Lakomá J; Rimondini R; Donadio V; Liguori R; Caprini M
PLoS One; 2014; 9(10):e108641. PubMed ID: 25337704
[TBL] [Abstract][Full Text] [Related]
4. Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain.
Notartomaso S; Mascio G; Bernabucci M; Zappulla C; Scarselli P; Cannella M; Imbriglio T; Gradini R; Battaglia G; Bruno V; Nicoletti F
Mol Pain; 2017 Jan; 13():1744806917697009. PubMed ID: 28326943
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-kappaB pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of L-acetylcarnitine.
Chiechio S; Copani A; De Petris L; Morales ME; Nicoletti F; Gereau RW
Mol Pain; 2006 Jun; 2():20. PubMed ID: 16764720
[TBL] [Abstract][Full Text] [Related]
6. L-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors.
Chiechio S; Caricasole A; Barletta E; Storto M; Catania MV; Copani A; Vertechy M; Nicolai R; Calvani M; Melchiorri D; Nicoletti F
Mol Pharmacol; 2002 May; 61(5):989-96. PubMed ID: 11961116
[TBL] [Abstract][Full Text] [Related]
7. Acetyl-L-carnitine in neuropathic pain: experimental data.
Chiechio S; Copani A; Gereau RW; Nicoletti F
CNS Drugs; 2007; 21 Suppl 1():31-8; discussion 45-6. PubMed ID: 17696591
[TBL] [Abstract][Full Text] [Related]
8. N-Acetyl-cysteine causes analgesia by reinforcing the endogenous activation of type-2 metabotropic glutamate receptors.
Bernabucci M; Notartomaso S; Zappulla C; Fazio F; Cannella M; Motolese M; Battaglia G; Bruno V; Gradini R; Nicoletti F
Mol Pain; 2012 Oct; 8():77. PubMed ID: 23088864
[TBL] [Abstract][Full Text] [Related]
9. Characterization of small fiber pathology in a mouse model of Fabry disease.
Hofmann L; Hose D; Grießhammer A; Blum R; Döring F; Dib-Hajj S; Waxman S; Sommer C; Wischmeyer E; Üçeyler N
Elife; 2018 Oct; 7():. PubMed ID: 30328411
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 2 or 9 in α-galactosidase A-deficient mice.
Hayashi Y; Sehara Y; Watano R; Ohba K; Takayanagi Y; Muramatsu K; Sakiyama Y; Mizukami H
J Gene Med; 2023 Dec; 25(12):e3560. PubMed ID: 37392007
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of mGlu2 receptors via NF-κB p65 acetylation is involved in the Proneurogenic and antidepressant effects of acetyl-L-carnitine.
Cuccurazzu B; Bortolotto V; Valente MM; Ubezio F; Koverech A; Canonico PL; Grilli M
Neuropsychopharmacology; 2013 Oct; 38(11):2220-30. PubMed ID: 23670591
[TBL] [Abstract][Full Text] [Related]
12. Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach.
Klug K; Spitzel M; Hans C; Klein A; Schottmann NM; Erbacher C; Üçeyler N
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895103
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of Immune Response Mediators and Pain-Related Ion Channels Is Associated with Pain-like Behavior in the GLA KO Mouse Model of Fabry Disease.
Spitzel M; Wagner E; Breyer M; Henniger D; Bayin M; Hofmann L; Mauceri D; Sommer C; Üçeyler N
Cells; 2022 May; 11(11):. PubMed ID: 35681422
[TBL] [Abstract][Full Text] [Related]
14. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Strategy for Fabry Disease by Intravenous Administration of Adeno-Associated Virus 9 in a Symptomatic Mouse Model.
Hayashi Y; Sehara Y; Watano R; Ohba K; Takayanagi Y; Sakiyama Y; Muramatsu K; Mizukami H
Hum Gene Ther; 2024 Mar; 35(5-6):192-201. PubMed ID: 38386497
[TBL] [Abstract][Full Text] [Related]
16. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
17. Altered globotriaosylceramide accumulation and mucosal neuronal fiber density in the colon of the Fabry disease mouse model.
Masotti M; Delprete C; Dothel G; Donadio V; Rimondini R; Politei JM; Liguori R; Caprini M
Neurogastroenterol Motil; 2019 Mar; 31(3):e13529. PubMed ID: 30609268
[TBL] [Abstract][Full Text] [Related]
18. Stratification of Fabry mutations in clinical practice: a closer look at α-galactosidase A-3D structure.
Rickert V; Wagenhäuser L; Nordbeck P; Wanner C; Sommer C; Rost S; Üçeyler N
J Intern Med; 2020 Nov; 288(5):593-604. PubMed ID: 32583479
[TBL] [Abstract][Full Text] [Related]
19. Ion channels and pain in Fabry disease.
Weissmann C; Albanese AA; Contreras NE; Gobetto MN; Castellanos LCS; Uchitel OD
Mol Pain; 2021; 17():17448069211033172. PubMed ID: 34284652
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development.
Üçeyler N; Biko L; Hose D; Hofmann L; Sommer C
Mol Pain; 2016; 12():. PubMed ID: 27145802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
